BMI calculator with GLP-1 overlay
GLP-1 BMI Calculator
Three things at once: the number itself, whether it clears the bar the Wegovy and Zepbound trials set, and where the mean result from STEP-1, SURMOUNT-1 or ATTAIN-1 would leave you if you got it.
Your BMI
32.5
Obesity (Class 1)
Wegovy / Zepbound trial BMI criteria
✓ At 32.5 you are over the BMI 30 line, the figure the Wegovy and Zepbound trials used for obesity on its own.
Where you'd land at each trial endpoint
Each trial's published mean, applied to the BMI you started from — ATTAIN-1, SURMOUNT-1 and STEP-1.
Wegovy (semaglutide 2.4 mg)
STEP-1, NEJM 2021 · −14.9% mean
27.6
Overweight
Zepbound (tirzepatide 15 mg)
SURMOUNT-1, NEJM 2022 · −20.9% mean
25.7
Overweight
Foundayo (orforglipron)
ATTAIN-1, Foundayo USPI Section 14 · −11.1% mean
28.9
Overweight
What BMI is and what it isn't
Weight over height squared, in kg/m², and the WHO sorts adults into six bands with it: underweight, normal, overweight, and three classes of obesity [1, 2]. It screens populations; it diagnoses nobody. Muscle and fat weigh the same to it, where the fat sits makes no difference to it, and it misjudges athletes, older adults, and anyone whose build sits outside the middle of the distribution.
None of which stops it mattering. The FDA writes eligibility for these drugs in terms of BMI, so an imperfect measure is the one standing between a patient and a prescription [3, 4].
FDA eligibility for Wegovy and Zepbound
The Wegovy and Zepbound labels use the same words for chronic weight management. Both cover adults who have obesity, plus adults who are overweight and have at least one comorbid condition tied to their weight. Section 1 prints no BMI number. The numbers come from the trials in Section 14, and plans generally apply them [3, 4]:
- BMI ≥ 30 (any class of obesity), OR
- BMI ≥ 27 AND at least one weight-related condition alongside it — high blood pressure, sleep apnea, dyslipidemia, type 2 diabetes, or established cardiovascular disease.
Below 27, you are outside what those trials enrolled. Prescribing there happens, but rarely for weight management at that end of the range.
What the GLP-1 overlay shows
Underneath the result are cards for each phase 3 trial, showing the BMI and band you would reach on that trial's published mean:
- STEP-1 [5] — 68 weeks on semaglutide at 2.4 mg, for a mean of 14.9%
- SURMOUNT-1 [6] — 72 weeks on tirzepatide at 15 mg, for a mean of 20.9%
- ATTAIN-1 [7] — 72 weeks on orforglipron (Foundayo), for a mean of 11.1% at the 17.2 mg dose (Foundayo label [10])
The arithmetic is plain enough: starting BMI times (1 − mean loss percentage / 100). What any one person actually gets varies a great deal, and our weight loss calculator carries the cautious and optimistic ends of that range, week by week.
Important caveats
- It measures populations, not patients. The same number can sit on two people built entirely differently, carrying entirely different cardiometabolic risk.
- Clearing the label is the start, not the end. Insurers routinely stack their own conditions on top — proof of a lifestyle program, a BMI of 35 rather than 30, particular comorbidities. Our insurance employer checker.
- The spread around a mean is wide. Those figures average thousands of people. Between 10 and 15% of participants lost under 5% even on the maintenance dose, and around 10% lost a great deal more than the mean.
- Body composition matters more than total weight. In the trials' body-composition scans, lean tissue made up about a quarter (SURMOUNT-1) to roughly two-fifths (STEP-1) of what came off. See our muscle mass deep-dive.
- What happens when it stops. In the STEP-1 extension [8], people who stopped semaglutide had regained about two-thirds of what they lost a year later. In SURMOUNT-4 [9], people switched to placebo after losing 20.9% on tirzepatide regained 14.0% of their body weight over the next year. Our tapering guide.
Important disclaimer
Educational only, and not medical advice. BMI screens, it does not diagnose, and label eligibility is one consideration among many when a prescriber decides whether to start someone on a GLP-1. What individuals actually get varies widely. GLP Watchdog does not diagnose, does not treat, and does not tell you what to take.
References
- 1.World Health Organization. Body mass index — BMI — Global Database on Body Mass Index. WHO Nutrition. 2024. https://www.who.int/health-topics/obesity
- 2.Centers for Disease Control and Prevention. Adult BMI Categories — CDC Healthy Weight, Nutrition, and Physical Activity. CDC. 2024. https://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/index.html
- 3.Novo Nordisk Inc. WEGOVY (semaglutide) injection — US Prescribing Information, Section 1, Indications and Usage (obesity, or overweight with a weight-related comorbid condition), and Section 14, Clinical Studies (trials enrolled at BMI ≥ 30, or 27 to under 30 with a comorbidity). FDA Approved Labeling. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s026lbl.pdf
- 4.Eli Lilly and Company. ZEPBOUND (tirzepatide) injection — US Prescribing Information, Section 1, Indications and Usage (obesity, or overweight with a weight-related comorbid condition), and Section 14, Clinical Studies (trials enrolled at BMI ≥ 30, or 27 to under 30 with a comorbidity). FDA Approved Labeling. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf
- 5.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. PMID: 33567185.
- 6.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PMID: 35658024.
- 7.Eli Lilly and Company. FDA approves Lilly's Foundayo (orforglipron), the only GLP-1 pill for weight loss. Lilly Investor Press Release, April 1, 2026. 2026. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill
- 8.Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF; STEP 1 Study Group. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022. PMID: 35441470.
- 9.Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, Ahmad NN, Zhang S, Liao R, Bunck MC, Jouravskaya I, Murphy MA; SURMOUNT-4 Investigators. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024. PMID: 38078870.
- 10.Eli Lilly and Company Foundayo (orforglipron) tablets, prescribing information DailyMed (NLM). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
Related tools and research
- GLP-1 dose plotter — how the drug accumulates at each rung of the ladder
- GLP-1 unit converter — milligrams to syringe units, for a compounded vial
- Tirzepatide vs semaglutide head-to-head — full effect-size comparison
- Foundayo (orforglipron) approval deep-dive — the new oral option
Ready to start? GLP-1 providers we have vetted
Telehealth providers, vetted by us, prescribing GLP-1 online.
Vetted by our editors · no insurance required
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Embody
A flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies
From $79/mo
Get started →Collective
Flat any-dose pricing, if you can absorb a $199 annual membership on top
From $59/mo + membership
Get started →MyDrHank
An oral route if you will not self-inject
From $171/mo, prepaid
Get started →